| 8th Aug 2022 9:30 am |
RNS |
Preliminary results from SAVANNAH Phase 2 Trial |
| 8th Aug 2022 7:00 am |
RNS |
FRESCO-2 Study Has Met Primary Endpoint |
| 1st Aug 2022 12:04 pm |
RNS |
Interim Results and Business Updates |
| 1st Aug 2022 7:00 am |
RNS |
HUTCHMED Initiates Bridging Study of Tazemetostat |
| 15th Jul 2022 9:30 am |
RNS |
HUTCHMED Initiates Phase I Trial of HMPL-A83 |
| 13th Jul 2022 7:00 am |
RNS |
Results of SAVANNAH Global Phase II Trial at WCLC |
| 6th Jul 2022 7:00 am |
RNS |
First Participants in Phase I Trial of IMG-007 |
| 30th Jun 2022 9:30 am |
RNS |
Total Voting Rights |
| 29th Jun 2022 9:30 am |
RNS |
Blocklisting Six Monthly Return |
| 27th Jun 2022 9:30 am |
RNS |
HUTCHMED to Announce 2022 Half-Year Results |
| 1st Jun 2022 9:30 am |
RNS |
TAZVERIK® Approved in Hainan Pilot Zone |
| 24th May 2022 11:00 am |
RNS |
LTIP and Share Options |
| 16th May 2022 12:00 pm |
RNS |
Appointment of Non–Executive Director |
| 3rd May 2022 7:00 am |
RNS |
HUTCHMED Receives CRL from the US FDA |
| 27th Apr 2022 2:30 pm |
RNS |
Annual General Meeting Poll Results |
| 21st Apr 2022 9:30 am |
RNS |
Vesting of awards under Long Term Incentive Plan |
| 31st Mar 2022 7:00 am |
RNS |
Update on Status under HFCAA |
| 23rd Mar 2022 8:30 am |
RNS |
2021 Annual Report and Notice of AGM |
| 11th Mar 2022 9:00 am |
RNS |
Update on Status under HFCAA |
| 9th Mar 2022 8:30 am |
RNS |
Vesting of awards under Long Term Incentive Plan |
| 7th Mar 2022 7:00 am |
RNS |
HUTCHMED Receives $15m Milestone from AstraZeneca |
| 3rd Mar 2022 3:30 pm |
RNS |
Publication of Form 20-F |
| 3rd Mar 2022 12:30 pm |
RNS |
Retirement of CEO and appointment of new CEO |
| 3rd Mar 2022 12:00 pm |
RNS |
Full Year Results and Business Updates |
| 1st Mar 2022 8:30 am |
RNS |
Approval to Commercialize ELUNATE® in Macau |
| 7th Feb 2022 8:30 am |
RNS |
HUTCHMED to Announce 2021 Final Results |
| 4th Feb 2022 9:30 am |
RNS |
Phase Ib/II Combination Study of HMPL-453 |
| 20th Jan 2022 7:00 am |
RNS |
HUTCHMED Initiates Phase I Trial of HMPL-653 |
| 19th Jan 2022 7:00 am |
RNS |
HUTCHMED Data at ASCO GI Cancers Symposium |
| 17th Jan 2022 9:00 am |
RNS |
Holding(s) in Company |
| 12th Jan 2022 11:00 am |
RNS |
Breakthrough Therapy Designation for HMPL-523 |
| 10th Jan 2022 7:00 am |
RNS |
HUTCHMED Initiates Phase I Study of HMPL-760 |
| 31st Dec 2021 7:00 am |
RNS |
Blocklisting Six Monthly Return |
| 31st Dec 2021 7:00 am |
RNS |
Total Voting Rights |
| 20th Dec 2021 7:00 am |
RNS |
HUTCHMED Included in FTSE Russell Indexes |
| 15th Dec 2021 9:45 am |
RNS |
Grant of Share Options and Awards under LTIP |
| 14th Dec 2021 7:00 am |
RNS |
HMPL-523 Clinical Data Presented at ASH |
| 10th Dec 2021 10:00 am |
RNS |
HUTCHMED Presents Data at ESMO Immuno-Oncology ‘21 |
| 6th Dec 2021 7:00 am |
RNS |
HUTCHMED Completes Planned Enrollment of FRESCO-2 |
| 3rd Dec 2021 7:00 am |
RNS |
Updated NRDL to include ELUNATE and SULANDA |
